APO2370 SRL
7.9 FTEThe score of APO2370 shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +23 % Total assets -12 % Headcount (avg FTE) +41 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
APO2370's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 54,425 € | ||||
| Equity | 979,492 € | ||||
| Cash | 380,988 € | ||||
| EBITDA | 519,634 € | ||||
| Total assets | €3.86m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jun 2026
- Year ended 31 Dec 2024filed on 10 Jun 2025
- Year ended 31 Dec 2023filed on 04 Jun 2024
- Year ended 31 Dec 2022filed on 06 Jun 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
APO2370's financial analysis
- Solvency25.4%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of APO2370
APO2370's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0874.034.237
- VAT number
- BE0874034237
- Peppol
- Registered · 0208:0874034237 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 May 2005
- Registered office
- 2370 Arendonk
- Size
- Micro · 7.9 FTE
- Latest accounts
- 2025 · filed on 09 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
APO2370 (SRL) has been based in Arendonk since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 54,425 € and equity of 979,492 €; its revenue is not published. With 7.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 25.4%, below the median of its sector (44.2%).
Companies similar to APO2370
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DES Pagodes Manufacture of basic pharmaceutical products Genappe · balance sheet 383,064 €
- Tornaphar Retail sale of pharmaceutical products Tournai · balance sheet €3.74m
- EDEHealth Services Business and other management consultancy activities Beyne-Heusay · balance sheet 23,732 €
- Pharma2Care Retail sale of pharmaceutical products Zuienkerke · balance sheet €1.79m
- Limafran Retail sale of pharmaceutical products Lincent · balance sheet €2.00m
- Boskant Retail sale of pharmaceutical products Merchtem · balance sheet 729,117 €
- Apotheek Kestelyn Retail sale of pharmaceutical products Ypres · balance sheet €1.86m
- Inveda Retail sale of pharmaceutical products Ostend · balance sheet €13.6m
Frequently asked questions about APO2370
What is the revenue of APO2370?
APO2370 files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of APO2370?
In Belgium, the VAT number is the company number prefixed with BE: BE0874034237 for APO2370, if the company is VAT-registered. Its company number (CBE) is 0874.034.237.
Where is the registered office of APO2370?
According to the CBE register, the registered office of APO2370 is in 2370 Arendonk.
What is the equity of APO2370?
At the close of the 2025 financial year, the equity of APO2370 amounts to 979,492 €, a solvency of 25.4% of total assets.
How many people work at APO2370?
7.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages APO2370?
The register lists 2 active mandates at APO2370. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of APO2370
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →